Related Experiment Video

Updated: Aug 20, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Epidermal growth factor receptor-related peptide inhibits growth of PC-3 prostate cancer cells

Dorota J Marciniak1, Arun K Rishi, Fazlul H Sarkar

  • 1Departments of Internal Medicine and Pathology, John D. Dingell Veterans Affairs Medical Center, Karmanos Cancer Center, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.

Molecular Cancer Therapeutics
|January 7, 2005
PubMed

Insights

EGFR-related peptide (ERRP) effectively inhibits prostate cancer cell growth and induces apoptosis by blocking epidermal growth factor receptor (EGFR) signaling pathways. This suggests ERRP is a potential therapeutic agent for prostate carcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Targeting growth factor receptor activation, particularly epidermal growth factor receptor (EGFR), is a key strategy in developing targeted anticancer therapies.
  • EGFR-related peptide (ERRP), a negative regulator of EGFR, has shown potential as a therapeutic agent for colorectal cancer.

Purpose of the Study:

  • To investigate the potential of ERRP as a therapeutic agent for prostate carcinoma.
  • To examine the effects of ERRP on the PC-3 prostate cancer cell line and its associated signaling pathways in vitro.

Main Methods:

  • Treatment of PC-3 prostate cancer cells with recombinant ERRP.
  • Assessment of cell growth inhibition, apoptosis induction (caspase-3 activation, PARP cleavage), and EGFR signaling pathway modulation (Akt, MAPK, NF-κB activation).
  • Evaluation of ERRP's effect on transforming growth factor-alpha-induced cellular responses.

Main Results:

  • ERRP significantly inhibited PC-3 cell growth in a dose- and time-dependent manner.
  • ERRP induced apoptosis, evidenced by increased apoptotic cells and activation of caspase-3 and PARP.
  • ERRP attenuated EGFR signaling, including downstream Akt, MAPK, and NF-κB activation, and inhibited TGF-α-induced cell proliferation and EGFR activation.

Conclusions:

  • ERRP effectively inhibits prostate cancer cell growth and induces apoptosis by attenuating EGFR signaling.
  • ERRP demonstrates potential as a novel therapeutic agent for prostate cancer treatment.
  • ERRP's mechanism involves inhibiting EGFR activation, partly through increased ligand sequestration.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...